Multicenter Phase 1/1b Trial to Assess Safety and Preliminary Efficacy of Corvus’ Lead Oral Checkpoint Inhibitor and Genentech’s Atezolizumab to Treat Patients with Cancer

Burlingame, CA, October 26, 2015 – Corvus Pharmaceuticals, a private clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer therapies by harnessing the immune system, announced today that it entered into a clinical trial collaboration agreement with Genentech, a member of the Roche Group. The companies will collaborate on a Phase 1/1b clinical trial assessing safety, tolerability and preliminary efficacy of Corvus’ lead oral small molecule immune checkpoint inhibitor, CPI-444. The successive expansion cohort Phase 1/1b trial will examine activity of CPI-444 both as a single-agent and in combination with Genentech's investigational cancer immunotherapy atezolizumab (MPDL3280A).  Atezolizumab is a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1 (PD-L1). The clinical trial is scheduled to begin in the first quarter of 2016 and will enroll patients with diverse types of solid tumors.  Corvus retains global rights to CPI-444.

“We are pleased to enter into this clinical trial collaboration with Genentech, a global leader in the development of transformative treatments for patients with cancer and a leader in the field of immuno-oncology,” said Richard A. Miller, M.D., an oncologist and chief executive officer of Corvus Pharmaceuticals. “Through this collaboration we will advance CPI-444 and explore its clinical benefit as a single agent and in combination with Genentech’s atezolizumab.”

About Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T cells. For more information, visit www.corvuspharma.com.

Investor Contact:

Leiv Lea
Chief Financial Officer 
LLea@corvuspharma.com
650-900-4522

Media Contact:

David Walsey
BrewLife
dwalsey@brewlife.com
858-617-0772